Treatment of Androgenetic Alopecia in Females, 9 Beam
- Conditions
- Hair LossAndrogenetic AlopeciaFemale Pattern Baldness
- Interventions
- Device: Control DeviceDevice: HairMax LaserComb
- Registration Number
- NCT00981461
- Lead Sponsor
- Lexington International, LLC
- Brief Summary
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Detailed Description
This is a randomized double-blind, control device clinical study across 5 sites, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).
The trial with 60 female subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.
Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.
Initial efficacy endpoint for each subject will be assess at visit 4 (week 16).
Safety analysis will be assessed based on the reports of adverse events during study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 72
- Diagnosis of androgenetic alopecia
- Fitzpatrick Skin Types I-IV
- Ludwig I-4, II-1, II-2, or frontal
- Active hair loss within last 12 months
- Photosensitivity to laser light
- Malignancy in the target area
- Pregnancy
- Lactating females
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description control device Control Device control device LLT Device 2009 9 Beam HairMax LaserComb HairMax LaserComb
- Primary Outcome Measures
Name Time Method Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline Baseline, 16 weeks, 26 weeks The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
David Goldberg, MD
🇺🇸Hackensack, New Jersey, United States
Jose Mendez, DO
🇺🇸Miami, Florida, United States
Sadick Research Group
🇺🇸New York, New York, United States
Abe Marcadis, MD
🇺🇸Palm Beach, Florida, United States
Janet Hickman, MD
🇺🇸Lynchburg, Virginia, United States